ARTICLE / CLIENT ALERT
IRS Issues Guidance on the Deductibility of Fertility Treatments for Same-Sex Couples
July 28, 2021
Read time: 8 min
On April 9, 2021, the Internal Revenue Service (IRS) released PLR 202114001 (PLR), which provides guidance on the deductibility of medical costs under Section 213 of the Internal Revenue Code (Code) relating to fertility expenses for same-sex couples. While the PLR disallows most of the costs incurred by a same-sex couple wishing to have a child, the IRS’ distinction between deductible costs for medical procedures attributable to the taxpayer and non-deductible costs for medical procedures attributable to third parties raises unique concerns about the equitable treatment of different taxpayers.
The PLR responded to a request for a ruling on the deductibility of medical costs arising from egg donation, in vitro fertilization (IVF) procedures and gestational surrogacy for a male same-sex couple (Taxpayers A and B, collectively the Taxpayers). The Taxpayers were legally married and wished to have a child with as much of their representative DNA as possible. As such, the Taxpayers planned for Taxpayer A to donate sperm and for Taxpayer B’s sister to donate the egg, with an unrelated third party used as a gestational surrogate to carry the resulting child to term. The Taxpayers sought a ruling under Section 213, authorizing deductions for costs and fees relating to egg retrieval, sperm donation, sperm freezing, IVF medical procedures, surrogate childbirth expenses, surrogate medical insurance, legal and agency fees relating to the surrogacy and other medical expenses arising from the surrogacy.
The IRS concluded that the costs and fees related to egg donation, IVF procedures and gestational surrogacy would not qualify as deductible medical expenses under Section 213 when they are incurred for third parties, such as Taxpayer B’s sister and the proposed surrogate. In contrast, medical costs and fees directly attributable to the taxpayers are deductible within the limitations of Section 213, including sperm donation and sperm freezing.
LEGAL BACKGROUND
The IRS considered several key authorities before arriving at its conclusion. Establishing the statutory structure for the deductions, Section 213(a) of the Code allows a deduction of expenses paid for medical care of the taxpayer to the extent they exceed 7.5% of the their adjusted gross income. Critically, “medical care of the taxpayer” is read to include only those costs and fees directly attributable to the taxpayer, the taxpayer’s spouse or the taxpayer’s dependents, thus excluding third-party egg donors or gestational surrogates.
Section 213(d)(1)(A) of the Code provides that medical care includes amounts paid for the diagnosis, cure, mitigation, treatment or prevention of disease or for the purpose of affecting any structure or function of the body. Medical care is thus divided into two distinct qualifying definitions: Those amounts paid to treat a medical condition or defect and those amounts paid for the purpose of affecting any structure or function of the body.
The PLR provides multiple authorities that examine the contours of the medical expense deduction under the first qualifying definition of care relating to a medical condition. For instance, Atkinson v. Commissioner, 44 T.C. 39 (1965) and Magdalin v. Commissioner, T.C. Memo 2008-293, aff’d without published opinion, 105 A.F.T.R.2d (RIA) 2010-442 (1st Cir. 2009) both support the general proposition that the deduction has historically been construed narrowly.
Under the second qualifying definition of medical care relating to the structure and function of the body, Revenue Ruling 73-201 (1973-1 CB 140) and Revenue Ruling 73-603 (1973 CB 76) are referenced to provide additional guidance in the specific context of medical treatments affecting fertility. These rulings hold that the costs associated with vasectomies and operations that render a woman incapable of having children affect a structure or function of the body and therefore qualify as a deductible medical expense within the limitations of Section 213.
The IRS finally provides a number of illustrative cases. In Magdalin, the US Tax Court considered surrogacy and egg donor expenses claimed by a single, heterosexual male and held that costs incurred in fathering children through unrelated egg donors and gestational carriers are not deductible medical expenses under Section 213. The deductions were denied because there was not a causal relationship between an underlying medical condition or defect and the taxpayer’s expenses nor were the costs incurred for the purpose of affecting a structure or function of the taxpayer’s body. Longino v. Commissioner, T.C. Memo 2013-90, aff’d 593 Fed. Appx. 965 (11th Cir. 2014) ruled similarly, with the Tax Court holding that a taxpayer cannot deduct IVF costs of an unrelated person if the taxpayer does not have a defect which prevents them from naturally conceiving children. In Morrissey v. United States, 871 F.3d 1260 (11th Cir. 2017), a male taxpayer in a same-sex union sought to deduct costs he incurred to retain, compensate and care for the woman serving as the egg donor and gestational surrogate. Morrissey characterized himself as “effectively,” if not medically, infertile because he is homosexual, prompting the court to consider whether the expenses were incurred for the purpose of affecting Morrissey’s bodily reproductive function. The court found that the IVF costs were not deductible under Section 213(d) because the costs were not for materially influencing or altering an action for which the taxpayer’s own body was specifically fitted, used or responsible. Since the IVF and surrogacy procedures did not materially affect the structure and function of the taxpayer’s body, they did not qualify under the second definition of “medical expenses.”
POLICY OUTLOOK
Providing guidance on the deductibility of medical costs could not have been an easy task for the IRS. The current legal regime under Section 213 presents a consistent and structured analytical framework for examining the deductibility of costs associated with fertility-related medical procedures. However, it also introduces certain equity concerns between taxpayers.
The PLR is somewhat rare in that the Taxpayers were advised that the IRS would likely issue an adverse ruling and choose to proceed with their request. This decision explicitly highlights the complex nature of this portion of the Code, raising the possibility that it may need to be revisited to ensure taxpayers receive fair treatment. Where this cannot be accomplished through IRS or US Department of the Treasury guidance, it may indicate the need for a legislative solution.
Mechanically, it might be argued that limiting the applicability of the deduction prevents income shifting between various taxpayers. Under the PLR, unless the taxpayer is medically infertile, only third-party egg donors and surrogates can deduct medical costs relating to IVF procedures because of the affect such a process would have on the structure and function of their body. If such a deduction were allowed to taxpayers without medical infertility, it might be favorable to shift the deduction between the couple and the surrogate depending on their financial circumstances. Thus, the limitation on the deduction may ensure equitable tax treatment between the various parties by preventing income shifting.
Conversely, because of the structure of Section 213 and the definition of “medical costs” as interpreted by the PLR, couples seeking the same medical procedures for the same purpose of conceiving a child may face different tax treatment depending on their medical circumstances or family structure.
For example, a different-sex couple experiencing medical infertility would likely find their medical costs relating to IVF procedures deductible under the PLR framework. A different-sex couple that does not experience medical infertility but is faced with other legitimate medical reasons for pursuing IVF procedures, such as dormant genetic disorders at risk of passing on to the child, would likely find the same medical costs non-deductible. Thus, while both couples are presented with the option between conceiving naturally or through IVF procedures, the PLR framework would likely only allow the deduction to the first couple despite the second couple’s legitimate reasons for pursuing IVF procedures.
Even stranger results may arise in the context of same-sex couples. The existing legal regime seems to imply that a same-sex couple faced with medical infertility would likely find their medical costs relating to IVF procedures deductible. In comparison, a same-sex couple that does not experience medical infertility would likely find the same costs non-deductible. From a practical point of view, neither couple would be capable of directly conceiving a child together. However, simply because of the differences in their medical circumstances, one couple would be able to access a deduction while the other would not.
In light of social and legal developments surrounding same-sex couples—and confronted by the practical realities of modern families—a reassessment of this analytical framework may be necessary for equitable treatment between taxpayers.
Anthony Teng, a summer associate in the New York office, also contributed to this article.

Vaccinated and Masked: CDC Changes Course, Recommends Vaccinated Individuals Mask Indoors Where COVID-19 Transmission is “Substantial or High”
ARTICLE / CLIENT ALERT
Vaccinated and Masked: CDC Changes Course, Recommends Vaccinated Individuals Mask Indoors Where COVID-19 Transmission is “Substantial or High”
July 27, 2021
Read time: 5 min
On July 27, 2021, the US Centers for Disease Control and Prevention revised its COVID-19 mask guidance, recommending that fully vaccinated individuals should wear a mask in indoor public spaces if they are located in areas of “substantial or high” levels of community transmission. Employers should review their mask policies for employees in light of this new recommendation.
On July 27, 2021, the Centers for Disease Control and Prevention (CDC) issued new COVID-19 mask guidance for the general public, including US-based workforces. Specifically, the CDC recommends that fully vaccinated individuals should wear a mask indoors in public if they are located in an area of “substantial or high” levels of community transmission.
The CDC maintains a map showing the level of transmission in each county over a specified seven-day period. As of July 27, 2021, 63.45% of US counties were at “substantial” or “high” levels of community transmission, meaning the county saw at least 50 new cases per 100,000 persons (i.e., at least 8% of COVID-19 tests were positive) during the past seven days.
This new guidance is in stark contrast to the CDC’s May 2021 recommendation that fully vaccinated individuals no longer needed to wear masks in most situations. CDC Director Rochelle Walensky stated that the change in guidance is “to help prevent the spread of the Delta variant and help protect others” in response to a recent rise in COVID-19 cases. While Walensky stated that vaccinated individuals represent a “very small amount of transmission” and the overwhelming majority of new infections, hospitalizations and deaths due to COVID-19 are occurring in unvaccinated individuals, vaccinated people can still contract the virus and pass it to others.
While CDC guidance is not a legal requirement, it is expected that many state and local governments will follow suit with orders requiring compliance with this latest CDC standard. In fact, prior to the CDC announcement, some counties such as Los Angeles, California, and St. Louis, Missouri, had already reinstated mask mandates.
Employers should work closely with legal counsel to monitor jurisdictions where they operate. Those with dual-level workplace mask policies—requiring masks for unvaccinated employees, while remaining silent as to masks for fully vaccinated employees—should review such policies in light of this new CDC guidance, and in conjunction with review of levels of community transmission in their communities of operation.
Questions? We are here to help. Please feel free to reach out to your McDermott attorney for more information.

Can Employers Offer COVID-19 Vaccine Incentives for Employees?
ARTICLE / CLIENT ALERT
Can Employers Offer COVID-19 Vaccine Incentives for Employees?
July 27, 2021
Read time: 4 min
Can employers offer incentives for employees to get a COVID-19 vaccine? In short, yes. Incentives may take many forms, such as a one-time bonus, a gift card or a few extra vacation hours. Employers can get creative.
There are two issues to consider when implementing a vaccine incentive program for purposes of complying with employment and benefits laws: the concepts of coercion and reasonable accommodation.
INCENTIVES: HOW MUCH IS TOO MUCH?
Employers must carefully consider the value of the offered incentive if they plan to administer the vaccines themselves or through a contracted third party. As of May 2021, the US Equal Employment Opportunity Commission (EEOC) provided additional clarity on this issue.
If employers (or their contractors) are providing the vaccination to the employees, then employers cannot offer an incentive that is so substantial as to be coercive. This is because COVID-19 vaccinations require employees to answer pre-vaccination disability-related screening questions; employers are generally limited in their ability to ask employees for disability-related information. Limited exceptions include instances where the information is job-related and consistent with business necessity or where the information is disclosed voluntarily as part of a wellness program.
When an employer (or its contractor) is administering the vaccine and offering a very large incentive, the EEOC cautions that this could make employees feel pressured to disclose medical information that is protected under the Americans with Disabilities Act (ADA), rendering the disclosure non-voluntary and in violation of the ADA. The EEOC has not given employers direct feedback on what qualifies as “substantial” or “coercive” in this context, other than now-rescinded guidance that a water bottle is not coercive, but a gym membership is. (On balance, a few hours of paid time off seems to fall toward the non-coercive side of the scale.). In addition, if the employer (or their contractors) are administering the vaccine, this could unintentionally create a “group health plan” under the Employee Retirement Income Security Act of 1974 (ERISA); this would create unforeseen employer compliance obligations.
The above “coercion” and ERISA issues do not apply if the employer is simply offering a program where the employer gives employees an incentive payment or perk in exchange for the employee providing the employer with proof of vaccination (assuming the employer is not the vaccinator). If employees obtain vaccinations elsewhere and provide proof of vaccination, then the employer can offer any incentive of any size. This is because asking for proof of vaccination alone is not a disability-related inquiry under the ADA, and therefore the employer is not seen as “coercing” disability-related information from employees. With such proof-of-vaccination programs, employers should explicitly caution employees not to provide medical or genetic information when providing proof of vaccination.
ALTERNATIVE WAYS TO OBTAIN THE INCENTIVE
There may be employees who cannot obtain a COVID-19 vaccination due to a legally-protected reason (such as religion or disability) and thus cannot obtain the incentive or perk by way of vaccination (or proof of vaccination). In such case, employers should consider whether a reasonable accommodation can be provided to permit the employee to obtain the perk in an alternate way, unless doing so would pose an undue burden.
Employers should also consider whether any non-cash perks given to employees will be considered taxable income to the employee. Perks could be excludable from income if they are “de minimis” in the view of the Internal Revenue Service (IRS).

States replenish ICSID roster
ARTICLE
States replenish ICSID roster
July 14, 2021
Read time: 1 min
Lisa Richman has been appointed to ICSID’s panel of arbitrators in Uzbekistan.
CMS Addresses Virtual Care Expansion in CY 2022 Medicare Physician Fee Schedule Proposal
ARTICLE / CLIENT ALERT
CMS Addresses Virtual Care Expansion in CY 2022 Medicare Physician Fee Schedule Proposal
July 26, 2021
Read time: 7 min
On July 23, 2021, the Centers for Medicare & Medicaid Services (CMS) published its annual proposed changes to the Medicare Physician Fee Schedule (MPFS), which include several key telehealth and other virtual care-related proposals. The proposals address long-standing restrictions that have historically limited the use of telehealth and virtual care, including geographic and originating site restrictions, and limitations on audio-only care, as well as coverage extensions for some services added during the COVID-19 public health emergency.
These proposals include:
- The implementation of the Consolidated Appropriations Act, 2021 (CAA) in-person visit requirement for mental health services that either do not meet Medicare’s typical geographic restrictions or occur when the originating site is the patient’s home, regardless of geography
- The ability for certain mental health services to be delivered via audio-only communications when patients are located in their homes (however, in these cases, the provider would also be required to comply with the in-person visit requirement described above)
- The extension of coverage of the services temporarily added to the Medicare telehealth services list (Category 3 services) through the end of CY 2023 to allow more time for evaluation, and the rejection of proposed new, permanent Medicare telehealth services
- The permanent adoption of HCPCS Code G2252 for extended virtual check-ins, which was established on an interim basis in the CY 2021 MPFS.
1. Removal of geographic restriction and originating site requirements for mental and behavioral health services if an in-person visit is provided within six months prior to the initial visit and every six months thereafter
In the CAA, Congress removed the baseline geographic restrictions on the coverage of telehealth services, and added the home of a Medicare beneficiary as a permissible originating site for the diagnosis, evaluation or treatment of a mental health disorder. While tele-mental health advocates generally viewed this as a positive change, in order for providers to take advantage of these additional flexibilities, Congress added a requirement that they furnish a covered service in person to the patient within six months prior to the initial telehealth services, and then periodically on a schedule determined by CMS. The in-person requirement was not extended to telehealth services for diagnosed substance use disorder or co-occurring mental health disorders, for which the home is a qualifying site and geographic restrictions do not apply.
Many observers interpreted this in-person requirement as necessitating an in-person visit before CMS would cover any telehealth services for the diagnosis, evaluation or treatment of a mental health disorder. In the CY 2022 MPFS, however, CMS clarifies that the in-person requirement only applies in situations where the telehealth service is not provided for purposes of diagnosis, evaluation or treatment of a mental health disorder other than for treatment of a diagnosed substance use disorder or co-occurring mental health disorder, and only in locations that do not meet the geographic restrictions or when the originating site is the home of the patient, regardless of geography. CMS seeks comment on whether to adopt a claims-based mechanism to distinguish between mental health services that are subject to the in-person requirement and those that are not, and on whether the agency should issue a regulation that clarifies the scope of the in-person requirement.
With respect to subsequent in-person evaluations, CMS proposes to require that they occur at least every six months before each telehealth service furnished for the diagnosis, evaluation or treatment of mental health disorders by the same practitioner. CMS also seeks comment on whether the in-person service could also be furnished by another physician or practitioner of the same specialty and same subspecialty within the same group as the physician or practitioner who furnishes the telehealth service, either without limitation or only when the physician or practitioner who furnishes the telehealth service is unavailable or the two professionals are practicing as a team. CMS notes that although the language of the CAA states that the physician or practitioner furnishing the in-person, non-telehealth service must be the same person as the practitioner furnishing the telehealth service, it has under several circumstances historically treated the billing practitioner and other practitioners of the same specialty or subspecialty in the same group as if they were the same individual (e.g., for purposes of deciding whether a patient is a new or established patient, or whether to bill for initial or subsequent visit, practitioners of the same specialty/subspecialty in the same group are treated as the same person).
2. Reassessment of CMS’s interpretation of “interactive communications technology” to permit audio-only telehealth services for certain mental health services
CMS proposes to amend its definition of the term “interactive communications technology,” which has historically required all telehealth services to be delivered via a two-way, real-time audiovisual encounter, to include certain audio-only communications. Audio-only was added as a permissible modality for certain services during the public health emergency (PHE), and CMS found that many of the audio-only services delivered during the pandemic were for mental health treatment. Because of this prevalence and the fact that mental health services primarily involve verbal conversation, CMS proposes to limit the expanded definition to communications between established patients receiving mental and behavioral health counseling and therapy services (including opioid treatment programs). Such audio-telehealth services would only be permitted when patients are located in their home and when such patients either have technical limitations or choose not to use interactive video. These services also would be subject to the same in-person visit requirement that applies to mental health services delivered via other types of telehealth when the patient is located in the home. Providers would also be required to certify to the capability to provide services using two-way audiovisual technology using a new modifier proposed by CMS. All other telehealth services would be required to be conducted with real-time audio-video interactive technology.
3. Extension of coverage to the end of CY 2023 for services temporarily added to the Medicare Telehealth Services List during the COVID-19 PHE
Before the COVID-19 PHE, in order to be covered by Medicare and included on the Medicare Telehealth Services List, a telehealth service was required to meet one of two sets of criteria: the service either had to be similar to professional consultations, office visits and office psychiatry services specifically enumerated in the statute as constituting telehealth (Category 1 services), or, if not similar, the service had to be accurately described by the corresponding code when furnished via telehealth and have a demonstrated clinical benefit when delivered via telehealth (Category 2 services).
In the CY 2021 MPFS, CMS established a Category 3 telehealth services list as a way of identifying a subset of the temporarily covered telehealth services for limited continued coverage after the end of the PHE, during which time CMS would evaluate the services for permanent inclusion under its Category 1 and Category 2 criteria. In the CY 2022 MPFS, CMS proposes to extend coverage of Category 3 telehealth services to the end of CY 2023. CMS believes extending the time “will allow us time to collect more information regarding utilization of these services during the pandemic, and provide stakeholders the opportunity to continue to develop support for the permanent addition of appropriate services to the [Medicare Telehealth Services List] through our regular consideration process, which includes notice-and-comment rulemaking.” CMS also solicits comment on whether any of the services temporarily added to the Medicare Telehealth Services List should be now added to the Category 3 list.
CMS declined to add any of the services that had been requested for inclusion on the Medicare Telehealth Services List. CMS determined that none met the criteria for permanent inclusion under Category 1 or Category 2 for a variety of reasons, which may be instructive for those seeking ways to expand telehealth reimbursement opportunities.
4. Permanent Adoption of the Virtual Check-In (Code G2252)
In the CY 2021 MPFS Final Rule, CMS established, on an interim basis, code G2252 for an extended virtual check-in (11-20 minutes), which allows healthcare providers to briefly check in with an established patient using any form of synchronous communication technology, including audio-only. CMS proposes to permanently adopt coding and payment for code G2252.

Updated Workplace COVID-19 Guidance Gives Employers More Flexibility and Responsibility
ARTICLE / CLIENT ALERT
Updated Workplace COVID-19 Guidance Gives Employers More Flexibility and Responsibility
July 22, 2021
Read time: 9 min
On 19 July 2021, so-called “freedom day”, England moved onto Step 4 of its roadmap out of COVID-19 restrictions. In conjunction with this milestone, the UK Government released updated “working safely during coronavirus” guidance, effective from 19 July.
Most notably, the guidance no longer includes the instruction for staff to work from home if they can. However, the guidance urges caution and certainly does not encourage an immediate rush back to the office:
“During this period of high prevalence, the government expects and recommends a gradual return over the summer”.
“A new COVID-19 variant is spreading in some parts of England. There may be additional advice for your area”.
The guidance uses voluntary language rather than compulsory, but takes many opportunities to remind employers that they are legally obliged to safeguard workers’ health and safety, and to comply with other employment and equalities duties. A key effect of the change is to provide each employer with greater autonomy in how it satisfies those obligations in the context of its individual business and based on its own individual health and safety risk assessment.
This alert highlights the key points from the guidance as it relates to office environments. However, we recommend that anyone with responsibility for COVID-19 workplace health and safety (including in non-office workplaces) should read the guidance in full.
Risk Assessments
-
- Employers should update, and keep updated, existing workplace risk assessments taking the recommendations in the guidance into account.
- In order to carry out a suitable and sufficient risk assessment, employers should consider the different ways the virus can spread. The guidance explains that one of the main ways of spreading COVID-19 is by close contact with an infected person, who releases particles containing the virus when she breathes, speaks or coughs. Spread of the virus in this way may be prevented by:
– Ensuring adequate ventilation to mitigate the risk of aerosol spread of COVID-19. The new guidance puts much more emphasis on ventilation than previously. It encourages employers to use CO2 monitors to test how well ventilated office space is and maximise the supply of fresh air in office premises. Employers operating in buildings with sealed window units should consult with their building managers on the appropriate way to measure and maximise fresh air flow. This should include investigating whether the air conditioning system can be varied to increase fresh air within the building and considering limiting occupancy levels as a control measure.
– Encouraging use of outside space where possible.
– Putting in place measures to reduce face-to-face contact between people. The removal of the generally applicable social distancing rules means that there are no longer any limits on occupancy and/or physical distancing that apply across the board. However, the guidance still recommends taking steps that, in practice, may mean that fewer workers will be able to be in the office at any one time compared to pre-pandemic numbers. Suggested measures include installing screens or barriers, or using back-to-back or side-to-side working instead of face-to-face. In practice, many employers may determine that a reasonable degree of social distancing is required within their workplace to address risks identified by their own individual risk assessment.
– Using fixed teams or “cohorting” to reduce the number of people each person has contact with.
– Encouraging the use of face coverings by workers or customers in enclosed and crowded spaces. While face coverings will no longer required by law (other than where specifically mandated, for example, by Transport for London), the Government still expects them to be used “in crowded and enclosed places”. In an office environment, the guidance recommends measures to encourage workers to continue to wear masks in areas where they encounter people they aren’t usually in contact with and in “crowded and enclosed” places. No examples are given of what a crowded and enclosed place might be, and it is highly likely that different people will have very different views about what constitutes “crowded” in a pandemic environment. However, it seems likely that, based on their own business’s individual risk assessment, many employers will continue to require the use of face masks in communal areas, corridors, lifts, etc. Of course, consistent with obligations under equalities law, any requirement for workers to wear face masks must be adjusted as appropriate for those who are unable to wear them.
-
- Another way the virus may spread is via contaminated surfaces or belongings, which may be prevented by:
– Advising workers to wash their hands or use hand sanitiser frequently.
– Regularly cleaning surfaces. The guidance says that workstations should be assigned to an individual if possible. If they must be shared, there should be ways to clean them between each user.
Consultation
- The guidance reminds employers that they have a legal duty to consult with workers on health and safety matters, and encourages employers to listen to concerns raised by staff and explain how those will be addressed and the risk of COVID-19 managed.
- Once a risk assessment has been carried out, it should be shared with staff and, if the employer has more than 50 employees, it should be published on its website. It should also be kept under review and updated as and when necessary.
- Many businesses have already engaged in communication with staff about return to office matters. However, employers should not underestimate the wide range of views that staff may have about how things should be post “freedom day”. There may be some who think that restrictions are no longer necessary and others who would like all restrictions to remain in place. Some employees may also have concerns about work-related travel (particularly that which may involve using public transport). Employers should ensure that they engage with these concerns.
- Employers should explain their approach and the rationale for it. This will be particularly important if it is subsequently considered necessary to discipline those who refuse or fail to comply with ongoing restrictions or requirements.
Staff at Higher Risk
- High-risk people are no longer advised to shield. Therefore, the guidance encourages employers to pay particular attention to their concerns and circumstances. Individual needs should be discussed and precautions adopted as advised by their medical practitioner.
- However, there may be circumstances where it is not only the high-risk worker who needs to take a precaution, but those around them. For example, it may be appropriate for a worker who has not been, or does not wish to be, vaccinated to wear a face mask when in contact with a vulnerable colleague.
- This is where there is potential for a conflict of interest to arise between those who remain very concerned about their health and wellbeing and those who decide not to be vaccinated or object to being subject to any further restrictions.
Self-Isolation
- Self-isolation remains mandatory for those who test positive for or display symptoms of COVID-19, or who are a “close contact” of someone who tests positive. However, since 16 August 2021, those who have received a second vaccine at least 10 days before the contact will no longer be required to isolate, but should take a PCR test as soon as possible.
- Self-isolating workers who have taken a negative COVID-19 test may be able to return to work, although Government guidance recommends that if a person feels unwell despite having tested negative, he should stay at home until he feels well. However, the individual will still need to self-isolate if someone he lives with has tested positive or has symptoms and is awaiting a test result.
- The guidance reminds employers that if they know that a worker is self-isolating, it is an offence to allow that worker to attend work.
- Note that employers should not allow employees or visitors who display COVID-19 symptoms to enter the workplace.
Vaccinations
The guidance does not refer to vaccinations other than to remind employers that the mitigating steps should be taken even though workers may have been vaccinated.
Many employers are considering, or have considered, whether COVID-19 vaccination certification should form a part of facilitating a safe return to the workplace. The challenge in that approach, when health and safety can be safeguarded by taking the steps outlined in the guidance, is that vaccination is not mandatory, and there may be a range of reasons why a worker does not wish to be vaccinated, including those which are protected by UK discrimination laws.
The Government issued new guidance to employers on COVID-19 vaccination on 12 July 2021. It recommends that employers encourage their staff to get vaccinated and support them in doing so.
Conclusions and Next Steps
While many of the mandated steps that employers were required to take have gone, the obligation remains for employers to ensure that their workplace is safe in line with their underlying legal duties to protect the health and safety of their staff.
Employers will have more flexibility to determine what is appropriate for their particular workforces and workplaces, but also more responsibility for making, and being able to justify, decisions.
Employers should keep their risk assessments and mitigating steps under review and be responsive to changing circumstances and worker concerns.
Next Steps:
- Review and update your risk assessment in light of the new guidance and revise plans as necessary.
- Communicate with staff about your proposed next steps and consider their opinions and concerns. If you decide to favour one position over another, explain why, and keep a record of your thinking in case you need to evidence it at a later date.
- Educate and train line managers. Workers may have different views on several of the relevant issues. Some of those issues may be emotive, such as vaccination. It will be important to handle issues properly and consistently.
- If you require staff to return to the office, be prepared to deal with flexible working requests from those who wish to continue working from home. Again, it will be important to maintain a consistent approach to avoid any suggestion of unfairness or even disadvantage because of a protected characteristic.
- Take the time to liaise with any workers who are at higher risk or pregnant and to address their concerns.
If you would like to discuss the guidelines further, or their impact on any other type of work environment, please contact your usual McDermott lawyer.

Update on NY HERO Act
ARTICLE / CLIENT ALERT
Update on NY HERO Act
July 21, 2021
Read time: 4 min
As we have previously written “What Employers Need to Know About the NY HERO Act” and “Updated Vaccination Guidance and New York Law Developments,” the New York Health and Essential Rights Act (“HERO Act”) was signed into law to combat the spread of airborne infectious diseases in the workplace. On July 6, 2021, the New York State Department of Labor (“DOL”) published on its website a model airborne infectious disease exposure prevention plan, prevention standards and industry-specific airborne infectious disease prevention plans for the following industries: Agriculture, Construction, Delivery Services, Domestic Workers, Emergency Response, Food Services, Manufacturing and Industry, Personal Services, Private Education, Private Transportation and Retail. This publication triggers employers’ obligations under the HERO Act to adopt, post and disseminate prevention plans.
What Employers Need to Know
Under the HERO Act, employers are required to adopt airborne infectious disease prevention plans by Aug. 5, 2021. Employers may satisfy this requirement by adopting the DOL’s model prevention plan or, if applicable, the model standard relevant to their industry. Alternatively, employers may adopt an alternative prevention plan that meets the DOL’s minimum requirements, provided that the employer develops such plan with its collective bargaining representative, if any, or with the “meaningful participation” of its employees.
Once an employer has adopted a prevention plan, it has 30 days (no later than Sept. 4, 2021, depending on the date of adoption) to provide a copy of its prevention plan to all of its employees in writing in English and in the language identified by each employee as his or her primary language. “Employees” is broadly defined to include all full and part-time employees, independent contractors, workers hired through a staffing agency, domestic workers, home care and personal care workers, day laborers, etc. Copies of the employer’s prevention plan must be provided to new employees upon their hiring and must be made available upon request. The prevention plan must also be posted in a visible and prominent location within each worksite. If an employer provides an employment manual or handbook to its employees, a copy of its prevention plan must be included in such manual or handbook.
Although employers must adopt prevention plans by Aug. 5, 2021, they are not required to comply with, or enforce the terms of, their prevention plans until an airborne infectious disease is designated by the New York State Commissioner of Health as a highly contagious communicable disease that presents a serious risk of harm to the public health. At this time, no such designation has been made.
As always, if you have any specific questions about the HERO Act or how it impacts your organization, you should contact your SRZ attorney.
Authored by Mark E. Brossman, Ronald E. Richman, Scott A. Gold and Abdulrahman Alwattar.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

CMS Proposes Heightened Penalties and Additional Requirements under the Hospital Price Transparency Rule
ARTICLE / CLIENT ALERT
CMS Proposes Heightened Penalties and Additional Requirements under the Hospital Price Transparency Rule
July 20, 2021
Read time: 9 min
On July 19, 2021, President Joseph R. Biden’s administration released a proposed rule that would increase penalties for hospitals that do not comply with the Hospital Price Transparency Rule, effective January 1, 2022. The proposed rule also provides certain potentially burdensome clarifications and requests comment on further rulemaking activity relating to the Hospital Price Transparency Rule. Public comments to the proposed rule will be accepted until September 17, 2021.
The 2022 Medicare Outpatient Hospital Prospective Payment Rule (the proposed rule), includes a proposal from the Biden administration to dramatically increase penalties beginning on January 1, 2022, for hospitals that do not comply with the Hospital Price Transparency Rule. The proposed rule also includes additional, potentially burdensome, clarifications of the requirements for compliance with the Hospital Price Transparency Rule. For background on the Hospital Price Transparency Rule, please refer to our prior On the Subjects, CMS Finalizes Hospital Price Transparency Requirements, Disclosure of Negotiated Rates and Federal District Court Upholds Hospital Price Transparency Rule; Implementation and Compliance Questions Remain.
The Centers for Medicare and Medicaid Services (CMS) makes a number of proposals in the proposed rule, including variable penalties for noncompliance with the Hospital Price Transparency Rule, prohibitions on certain barriers to accessing the machine-readable file, and clarified requirements for price estimator tools. CMS also requests proposals on how CMS can ensure consumers understand the descriptions of shoppable services and that machine-readable files are standardized across hospitals. Public comments on the proposed changes and clarifications are due to CMS by September 17, 2021.
1. Sliding Penalties
The proposed rule includes changes that, if finalized, would increase potential civil monetary penalties (CMPs) for noncompliance with the Hospital Price Transparency Rule from a maximum of $109,500 per year to a sliding scale that would reach over $2 million per year for the largest hospitals. The CMP proposals are set forth in the following table:
| Number of Beds | Penalty Applied Per Day | Total Penalty Amount for Full Calendar Year of Noncompliance |
|---|---|---|
| 30 or less | $300 per hospital | $109,500 per hospital |
| 31 up to 550 | $310 – $5,500 per hospital (number of beds times $10) | $113,150 – $2,007,500 per hospital |
| >550 | $5,500 per hospital | $2,007,500 per hospital |
CMP amounts would be adjusted annually using a multiplier determined by the Office of Management and Budget based on the Consumer Price Index.
CMS notes in the proposed rule that it is concerned with a high rate of hospital noncompliance with the Hospital Price Transparency Rule, as identified by CMS through sampling and reviews to date. After considering a sliding CMP scale based on either hospital revenues or bed counts, CMS proposes using hospital bed counts, as specified in the most recently available, finalized cost report data.
CMS explains that its proposed daily penalty of $300 to $5,500 per day is commensurate with the level of severity of the potential violation, taking into consideration that nondisclosure of standard charges does not rise to the level of harm to the public as do other violations. It notes that the proposed maximum amounts generally align with other Department of Health and Human Services (HHS) initiatives, such as HIPAA-related CMPs.
CMS requests comments on the proposed sliding scale approach, including the penalty amounts, scaling factor (i.e., beds) and data sources (i.e., cost report). CMS requested comments on various questions relating to other aspects of the proposal, including the following:
- How should the nature, scope and severity of noncompliance be determined and applied for purposes of assessing CMPs?
- How should a hospital’s reason for noncompliance be determined, and are there bases for imposing lower CMPs, such as resource limitations or extreme or unusual circumstances?
- If multiple factors are used to scale the CMP amount, should there be a priority or weighting applied to specific factors?
2. Removing Barriers to the Machine-Readable File
CMS also proposes specifying in its regulations that hospitals must ensure standard charge information is easily accessible and without barriers, including, but not limited to, ensuring information is accessible to automated searches and direct file downloads through a link posted on a publicly available website. CMS notes a number of example “barriers,” including the following:
- Use of form submissions to access data
- Use of a “locked door” in front of content that makes it difficult or impossible for search engines to identify the data
- Use of Blocking codes, such as NOINDEX and “rel canonical” tagging, disallow statements, or removing the URL from the search index through the use of webmaster tools URL removal service
- Use of anti-automation tools that require users to pass tests proving they are human users, such as CAPTCHA and reCAPTCHA applications
- Use of pop-up windows that require a user to agree to all terms and conditions in a legal disclaimer
- Developing file constructs and web forms to obscure access to the data in a single machine-readable file through the use of Application Programming Interfaces (APIs), for example, using APIs calling for data that will not return a complete data file, do not provide supporting documentation on the use of the API, and do not allow a single query to return all data in a single machine-readable file
CMS requests comment on whether there are additional barriers that CMS should prohibit, and reserves the option to identify and add additional barriers in the future. CMS also requests comment on specific criteria that should be considered when evaluating whether a hospital displayed the machine-readable file in a “prominent manner,” and whether CMS should require hospitals to post machine-readable files using a CMS-specified URL or a standardized location (e.g., the hospital’s homepage).
3. Price Estimator Tool
CMS clarifies in the proposed rule that price estimator tools must provide a single dollar amount that is tailored to the individual seeking the estimate, taking the individual’s circumstances into consideration when developing the estimate. CMS further notes that the estimate must reflect the amount the hospital anticipates will be paid by the individual for the shoppable service, absent unusual or unforeseen circumstances. CMS notes that its reviews identified hospital price estimator tools that did not tailor a single estimated amount based on the individual’s circumstance, but instead provided estimated average amounts or ranges for the price of a shoppable service that appeared generated based on a broad population of patients, including outliers.
CMS requests comments on additional requirements for online price estimator tools, including best practices, common data elements and technical barriers to access.
4. Plain Language of Shoppable Services
The Hospital Price Transparency Rule required hospitals to provide a “plain language” description of each shoppable service for which it was posting standard charges and, in the proposed rule, CMS notes that some hospitals have used internal code descriptions instead of terminology that consumers may readily understand. CMS requested comment on whether it should require specific plain language standards, and if so, what those plain language standards should be.
5. Standardizing the Machine-Readable File
CMS recognizes in the proposed rule that the Hospital Price Transparency Rule took a relatively non-prescriptive approach to standard charge information to be displayed in the machine-readable file, but feedback from stakeholders indicates that more standardization of the machine-readable file may be necessary to meet the goal of permitting comparisons of standard charges from one hospital to the next. CMS requests comment on questions relating to a number of aspects of the machine-readable file, including the following:
- What are best practices for formatting data and should specific formats be required?
- Are there additional data elements that should be required (in addition to the charge, description, and common billing and accounting code)?
- What policies or incentives should CMS consider to improve standardization and comparability of these disclosures?
- What other policies should CMS consider to ensure the data posted by hospitals is accurate and complete?
Analysis and Takeaways
The proposed rule’s provisions relating to the Hospital Price Transparency Rule illustrate that price transparency holds bipartisan interest and that the Biden administration is seeking to further bolster a transparency framework initially developed by the Trump administration. Considering the conceptual alignment between the Hospital Price Transparency Rule and the Transparency in Coverage Rule set to become effective on January 1, 2022, it would appear unlikely that the Biden administration plans to pull back that correlating rule prior to its effective date.
Because the proposed rule would take a significantly different approach to CMPs as compared to the original Hospital Price Transparency Rule, certain stakeholders may view the proposed changes, if finalized, as grounds for litigation. At the same time, it would appear CMS’s underlying rationale for the increased penalties—that is, studies and reports of hospital noncompliance with the Hospital Price Transparency Rule—provide some support for the stated justification for the changes. Litigation against CMS may encounter headwinds, as the US Court of Appeals for the DC Circuit agreed with CMS’s expansive interpretation of its statutory authorization in prior Hospital Price Transparency Rule litigation (refer to the above-linked On the Subject for our analysis of that case).
In light of the significantly greater potential penalties for large hospitals and enhanced compliance obligation, we expect there will be a renewed focus on the mechanics of CMS’s authorization to impose CMPs. For example, CMS may impose a CMP only in cases where a hospital fails to respond to CMS’s request to submit a corrective action plan (CAP) or comply with the requirements of a CAP. CAPs are required in cases of “material violations” and CMS has established specific requirements for CAPs and provisions relating to noncompliance with CAPs. Interpretation and implementation of these provisions will be critical for hospitals that become subject to a CMS inquiry.
Stakeholders with an interest in the requirements of the machine-readable file should also take this opportunity to provide comments to CMS. The scope of CMS’s request for comments relating to the machine-readable file are broad, and we anticipate CMS may issue clarifications or requirements that create greater administrative burdens for hospitals that might involve a further review of commercial payor contracts. Comments and suggestions are most likely to be effective in cases where they can articulate how a proposal would further CMS’s transparency goals while also bringing clarity and reducing administrative burdens.

SPAC Litigation Alert: SPAC Sponsor and CEO Agree to Pay Civil Penalties and Forfeit Sponsor Shares Following SEC’s Charge of Disclosure and Due Diligence Failures
ARTICLE / CLIENT ALERT
SPAC Litigation Alert: SPAC Sponsor and CEO Agree to Pay Civil Penalties and Forfeit Sponsor Shares Following SEC’s Charge of Disclosure and Due Diligence Failures
July 20, 2021
Read time: 11 min
Throughout much of the COVID-19 pandemic, Special Purpose Acquisition Companies (“SPACs”) became an extraordinarily popular alternative to more traditional initial public offerings (“IPOs”). That rapid increase in popularity, with SPACs raising more in 2020 than the preceding decade, and more in the first quarter of 2021 than all of 2020, attracted significant attention from investors, sponsors, and, ultimately, regulators and the plaintiffs’ bar. Aggressive actions and statements by the SEC in early 2021, however, appear to have at least temporarily slowed new SPAC offerings.[1] While we expect the SPAC structure to remain attractive to prospective investors and sponsors and to continue to influence how private companies enter the public markets, the SEC’s latest warning shot described in this Alert illustrates the importance of ensuring that SPAC participants — particularly, SPAC sponsors — devote appropriate attention to legal and compliance matters, with a specific focus on ensuring robust diligence of prospective targets.
On July 13, 2021, the SEC signaled a further escalation of its scrutiny of the SPAC ecosystem by charging Stable Road Acquisition Company (“Stable Road”), a SPAC sponsor, its CEO, the acquisition target and the target’s own CEO for making false and materially misleading disclosures[2] in connection with a “de-SPAC transaction.”[3] While the SEC has been ramping up its investigations into SPAC participants since early 2021, this is only the second complaint it has filed in connection with a SPAC and the first to target liability under Exchange Act Section 14(a) for failing to conduct adequate due diligence of material misstatements incorporated into proxy material.[4] Along the way, however, SEC staff signaled that as part of their holistic scrutiny of each component of the SPAC lifecycle, that they would be carefully evaluating statements contained within proxy solicitations to SPAC investors.[5] Specifically, SEC staff’s public statements have made clear that in addition to liability under Section 10(b) and Rule 10b-5 based on trading in securities of the pre-merger SPAC and/or the post-merger company, any material misstatement or omission in connection with a proxy solicitation would also be subject to liability under Section 14(a) of the Exchange Act and Rule 14a-9 thereunder.[6]
While aggressive enforcement action by the SEC has been widely anticipated, the breadth and timing of the charges against participants in the Stable Road de-SPAC transaction is notable. The charges against the merger target, nascent space transportation company Momentus, Inc. (“Momentus”) and its CEO, Mikhail Kokorich, arise from a series of allegedly false or misleading statements that were communicated to both Stable Road and the associated private investment in public equity (“PIPE”) investors. Specifically, Momentus and its CEO allegedly misrepresented to Stable Road and to investors the results of tests performed on its equipment and technology, the national security issues faced by Kokorich, and its prospects of launching future space flights.[7] In addition, the SEC also charged Stable Road and Stable Road’s CEO, Brian Kabot, for failing to adequately investigate Momentus’ claims, which were incorporated into registration statements and proxy solicitations filed by Stable Road.[8] Without admitting or denying the SEC’s allegations, Momentus, Stable Road and Kabot have consented to more than $8 million in civil penalties.[9] Stable Road’s sponsor agreed to forfeit its rights to 250,000 founders shares, and Momentus and Stable Road granted a termination right to the investors in the PIPE offering.[10] Kokorich is contesting the SEC’s charges against him.
Flawed Due Diligence
As the SEC staff highlighted back in April 2021, liability under Exchange Act Section 14(a) and Rule 14a-9 is subject to a negligence standard.[11] The SEC charged Stable Road and its CEO with, inter alia, violating Section 14(a) and Rule 14a-9, for negligently soliciting investors with a proxy statement containing false and materially misleading statements.[12] Though the SEC did not allege that Stable Road and its CEO knew that the statements made by Momentus were false or misleading, it determined that Stable Road and its CEO performed inadequate due diligence of Momentus’ statements. While the Settlement Order does not specify the level of due diligence required to adequately investigate representations made in connection with registration statements or proxy solicitations, it appears to have premised its Section 14(a) and Rule 14a-9 negligence theory on Stable Road’s failure to adequately investigate Momentus’ claims. As SEC Chair Gary Gensler stated in connection with the Settlement Order’s press release, “the fact that Momentus lied to Stable Road does not absolve Stable Road of its failure to undertake adequate due diligence.”[13]
Notably, in assessing Stable Road’s due diligence effort, the SEC raised concerns that time pressure and financial incentives may compromise the ability for SPACs, their sponsors and other SPAC participants to conduct reasonable due diligence efforts. In connection with the due diligence performed by Stable Road, the SEC noted that Stable Road’s due diligence process was highly compressed due to the liquidation window detailed in its charter, a feature that is common to most SPAC structures. Specifically, Stable Road’s charter set an 18-month deadline to complete a merger or dissolve and return assets to shareholders. Due to delays in identifying a target, negotiating a deal and selecting a space technology consulting firm to assist it in conducting due diligence of Momentus’ technological claims, approximately 10 months remained before the deadline to consummate a deal.[14] The Settlement Order appears to suggest that this timing pressure resulted in Stable Road limiting its technology consultant to a “rapid technical assessment,” initially targeted to take two weeks, that did not include in its scope a number of material issues.
Impact on SPAC Acquisitions
The Stable Road case highlights the need for SPACs and their sponsors to undertake and document a thorough and complete due diligence process in connection with evaluating any prospective target business. Given the outcome in Stable Road, along with recent SEC staff statements focusing on the “de-SPACing” process in general, we expect a renewed focus on both the due diligence process within the SPAC space generally, and on disclosure related issues arising from statements pertaining to the performance and prospects of a target business. Notably, the SEC seeking specific protection for SPAC PIPE participants signals that the regulatory focus will not fall exclusively on the retail investor side. As SPAC PIPE arrangements are often crystallized prior to entry into a definitive merger or acquisition agreement — and well in advance of any proxy solicitation — disclosures provided in connection with such PIPE solicitations will likely get enhanced scrutiny from both SPACs and placement agents alike in view of the outcome in Stable Road. In addition to regulatory scrutiny, we expect the plaintiffs’ bar to look to Stable Road as a roadmap for future claims, both under federal securities laws and state fiduciary duty requirements. Close coordination between SPACs, their sponsors and deal counsel during both the due diligence and disclosure drafting process will remain imperative in view of the increasing scrutiny on SPAC business combinations generally.
Conclusion
The SEC’s flurry of statements and activity regarding SPACs likely portend an environment of further regulatory scrutiny of SPACs, their sponsors, targets, advisors, officers and affiliates. Increased regulatory scrutiny may also lead to follow-on civil litigation. SPACs and their sponsors must ensure that they take all appropriate and necessary steps to properly evaluate their combination targets. In addition, SPACs and their sponsors should perform robust and thorough due diligence, both on prospective targets generally, and to support representations made in connection with any de-SPAC transaction.
This is part of a series of SRZ Alerts regarding SPAC litigation. In addition to our robust SPAC transactions practice, which advises clients on SPAC IPOs and business combination transactions, SPAC sponsor investments, SPAC PIPEs and trading in SPACs generally, SRZ has a SPAC litigation task force advising, monitoring and advocating on SPAC litigation and regulatory developments. If you have any questions, please contact your attorney at Schulte Roth & Zabel or one of the authors.
Authored by Charles J. Clark, Douglas I. Koff, William H. Gussman, Jr., Ele Klein, Gayle R. Klein, Michael E. Swartz, Derek N. Lacarrubba, J. Eric Prather and Hannah Thibideau.
[1] See “SPAC Litigation Alert: SEC Cautions SPAC Participants that Claims of Reduced Liability Exposure Are Overstated,” SRZ Alert (April 13, 2021), available here.
[2] “SEC Charges SPAC, Sponsor, Merger Target, and CEOs for Misleading Disclosures Ahead of Proposed Business Combination,” SEC Press Release No. 2021-124 (July 13, 2021), available here (“SEC Press Release”).
[3] The SPAC lifecycle consists of two distinct phases. First, a shell company, is formed (the SPAC), which registers a securities offering and sells shares to investors to fund the future acquisition of one or more private companies. The proceeds from that sale are held in a trust until the eventual acquisition. In the second stage, the SPAC combines with a private company (i.e., the “de-SPAC” transaction), upon which the target, in effect, becomes a public company.
[4] In addition to Stable Road, the existence of five active SEC investigations of SPAC participants have been disclosed since the start of 2021: Clover Health, Lordstown Motors Corp., Canoo, MoneyLion and Akazoo SA. Prior to the SEC charging Stable Road, the SEC has so far only reached the complaint stage in Akazoo S.A. Specifically, in September 2020, the SEC filed a complaint against Akazoo S.A. (“SONG”), a post-merger company resulting from a de-SPAC transaction between Modern Media Acquisition Corp. and Akazoo Ltd., a private music streaming platform and technology company. The SEC’s charges against SONG included Section 10(b) and Rule 10b-5 claims based on false statements that were allegedly made in public reports while its shares traded publicly on the Nasdaq. Complaint, Securities and Exchange Commission v. Akazoo S.A., Docket No. 1:20-cv-08101 (S.D.N.Y. filed Sept. 30, 2020); Note that shareholders are separately maintaining a class action lawsuit against Akazoo S.A., Modern Media Acquisition Corp. (“MMAC”), a SPAC, and its directors and officers alleging material misstatements about Akazoo’s user base and competitive advantages in Akazoo’s registration and proxy statements. See Amended Complaint, In re Akazoo S.A. Securities Litigation, Docket No. 1:20-cv-01900 (E.D.N.Y. filed Sept. 8, 2020). Notably, in that case, the SEC did not actually allege misconduct by the SPAC itself. Id.
[5] See “SPACS, IPOs, and Liability Risk under the Securities Laws,” Securities and Exchange Commission Public Statement, Acting Director of Division of Corporation Finance, (April 8, 2021), available here.
[6] See id. The proxy solicitation process is regulated by Section 14(a) of the Exchange Act and Rule 14a-9, promulgated thereunder, which “prohibit the solicitation of proxies by means of materially false or misleading statements.” Virginia Bankshares, Inc. v. Sandberg, 501 U.S. 1083, 1087, 115 L. Ed. 2d 929, 111 S. Ct. 2749 (1991).
[7] See SEC Press Release.
[8] See id.
[9] See id. Note that all parties, including the sponsor, were also charged with violations of the anti-fraud provisions under Section 17(a) of the Securities Act.
[10] See SEC Press Release.
[11] In that statement, Director Coates reminded SPAC participants that liability under section 14(a) and Rule 14a-9 are generally subject to a “negligence” standard. “SPACS, IPOs, and Liability Risk under the Securities Laws,” Securities and Exchange Commission Public Statement, Acting Director of Division of Corporation Finance, (April 8, 2021), available here. See, e.g., Beck v. Dobrowski, 559 F.3d 680, 682 (7th Cir. 2009) (“There is no required state of mind for a violation of section 14(a); a proxy solicitation that contains a misleading misrepresentation or omission violates the section even if the issuer believed in perfect good faith that there was nothing misleading in the proxy materials”); Report of Investigation Pursuant to Section 21(a) of the Securities Exchange Act of 1934 and Commission Statement on Potential Exchange Act Section 10(b) and Section 14(a) Liability, Exchange Act Release No. 51283 (Mar. 1, 2005) (“Where the failure to make such disclosure is negligent, an issuer would violate Section 14(a) of the Exchange Act and Rule 14a-9 thereunder . . .”).
[12] In re Momentus, Inc. et al, Sec. Act Rel. No. 10955, Exch. Act Rel. No. 92391 (Jul. 13, 2021) at 12.
[13] See SEC Press Release.
[14] See In re Momentus at 3.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.
A Minimum Tax on Corporate Profits is Unfair
ARTICLE
A Minimum Tax on Corporate Profits is Unfair
July 19, 2021
Read time: 1 min
